Biotech Values

[DewDiligence]

FDA approves Tradjenta (linagliptin), a DPP-4 inhibitor from B-I/LLY:

http://finance.yahoo.com/news/FDA-Approves-Tradjenta-prnews-1957299504.html?x=0&.v=1

LLY paid B-I a large amount of money in Jan 2011 to collaborate on this and other diabetes drugs (#msg-58667443):

Under the terms of the agreement, Lilly agreed to pay 300 million euros up-front and to pay Boehringer another 625 million euros if the German company’s two oral diabetes medications meet certain regulatory milestones.

Tradjenta is one of the two aforementioned drugs.